Monopar reports positive preclinical imaging data for MNPR-101-Lu in pancreatic cancer model

Monopar Therapeutics

SPECT imaging shows high specificity and durable uptake of MNPR-101-Lu in tumor relative to normal tissue in human pancreatic cancer xenograft model.
Data help explain near complete tumor elimination observed after single injection of therapeutic radioisotopes bound to MNPR-101 in prior studies.
MNPR-101-Lu uses Lutetium-177, same therapeutic radioisotope as commercially successful Pluvicto and Lutathera.
Phase 1 dosimetry trial for diagnostic counterpart MNPR-101-Zr recently cleared by HREC in Australia for advanced cancer patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.